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Background: The ﬁndings of trials investigating the eﬀects of saﬀron (Crocus sativus L.) supplementation on
depression, anxiety, and C-reactive protein (CRP) are inconsistent. The current meta-analysis of randomized
controlled trials (RCTs) was carried out to assess the eﬀects of saﬀron (Crocus sativus L.) administration on
mental health parameters and CRP levels.
Methods: Two independent authors systematically searched online databases including EMBASE, Scopus,
PubMed, Cochrane Library, and Web of Science from inception until 30th July 2019. Cochrane Collaboration risk
of bias tool was applied to assess the methodological quality of included trials. The heterogeneity among the
included studies was assessed using Cochrane’s Q test and I-square (I2) statistic. Data were pooled using a
random-eﬀects model and weighted mean diﬀerence (WMD) was considered as the overall eﬀect size.
Results: Twenty one trials were included in this meta-analysis. Consumption of saﬀron resulted in a signiﬁcant
reduction in Beck Depression Inventory (BDI) (11 studies with 12 eﬀect size) (WMD: −4.86; 95 % CI: −6.58,
−3.14), Beck Anxiety Inventory (BAI) (5 studies) (WMD:−5.29; 95 % CI:−8.27,−2.31) and Pittsburgh Sleep
Quality Index (PSQI) scores (3 studies with 4 eﬀect size) (WMD:−2.22; 95 % CI:−2.73,−1.72). Saﬀron intake
did not aﬀect Hamilton Depression Rating Scale (HDRS-D), Hamilton Anxiety Rating Scale (HARS-A) scores and
C-reactive protein (CRP) levels.
Conclusions: This meta-analysis demonstrated that saﬀron intake signiﬁcantly reduced BDI, BAI and PSQI scores,
but did not aﬀect HDRS-D, HARS-A scores and CRP levels.
1. Introduction
Depression is one of the most prevalently diagnosed psychiatric
disorders. Almost, 1 in 5 adults in the US population report experien-
cing at least one period of major depression in their life, with women
having twice as big chance to develop depression and anxiety.1
Symptoms of depression include psychological parameters, physical
signs and behavioral symptoms, including depressed mood, loss of in-
terest to any action, pessimism, fatigue, feelings of worthlessness, re-
duced ably to think or concentrate, tearfulness, thoughts of suicide or
death and weight loss, sleep and appetite disorders and anhedonia.2,3
Patients with depression may suﬀer also from anxiety,4 another
common mental health disorder which is associated with poor quality
of life.5
Recently, cognitive behavior therapy (CBT) for mild to moderate
depression represents an attractive option for major depressive disorder
and insomnia.6 In a meta-analysis conducted by Okumura and Ichi-
kura,7 CBT had better performance compared to non-active treatments.
But this treatment is generally scarce by noncompliance and few
trained therapists. Therefore, Crocus sativus L. might be considered as
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an alternative therapy for mental disorder and metabolic syndrome.
Crocus sativus L., commonly known as saﬀron, belongs to the Iridaceae
family.8 The eﬀects of saﬀron occur due to three main secondary me-
tabolites, including crocin, picrocrocin and safranal.9,10 Current evi-
dence suggests the beneﬁcial eﬀects of saﬀron on parameters of mental
health and treatment of central nervous system disorders in patients
with depression and without depression. However, randomized clinical
trials (RCTs) of the eﬀects of saﬀron for treatment of depression and
anxiety have not been systematically evaluated and the results are
controversial. In a study by Ghajar et al.,11 30 mg/day of saﬀron ad-
ministration for 6 weeks to patients with major depressive disorder
(MDD) and anxious distress signiﬁcantly improved depression and an-
xiety scores. Taking 30 mg/day of crocin for 12 weeks by patients with
metabolic syndrome (MetS) reduced Beck Depression Inventory (BDI)
score.12 In another study, taking 30 mg/day Crocus sativus L. for 6
weeks had a signiﬁcant impact on Hamilton depression rating scale
(HDRS), i.e. it showed antidepressive eﬀects.13 However, ﬂuoxetine
combined with saﬀron (30 mg/day) for 4 weeks did not aﬀect BDI score
when compared with ﬂuoxetine as mono-therapy and placebo in pa-
tients with MDD.14
Although it has been proposed that saﬀron may improve parameters
of mental health, including depression and anxiety, the results of some
studies did not conﬁrm this.15 Therefore, this meta-analysis was per-
formed to summarize all the existing RCTs evidence and to evaluate the
eﬀects of saﬀron intake on parameters of mental health and CRP.
2. Materials and methods
The present study to the Preferred Reporting Items of Systematic
Reviews and Meta-Analysis (PRISMA) statement guideline for per-
forming and reporting.16
2.1. Search and studies selection strategies
Scientiﬁc international databases, including PubMed, Scopus, ISI
(Web of Science), Cochrane Central Register of Controlled Trials,
EMBASE, Google Scholar, contact with the authors and scanning the
reference list of included studies were searched for relevant studies
published from incent until 30th July 2019. A search strategy was de-
veloped using the following MeSH and text keywords; intervention,
(Crocus[MeSH] OR Crocus[tiab] OR colchicum[MeSH] OR colchicum
[tiab] OR "Crocus sativus"[MeSH] OR "Crocus sativus"[tiab] OR crocin
[tiab] OR crocetin[tiab] OR Saﬀron*[tiab] OR safranal[MeSH] OR sa-
franal [tiab]) AND (depression[MeSH] OR depression[tiab] OR "de-
pressive symptoms"[tiab] OR anxiety[MeSH] OR anxiety[tiab] OR
"beck depression inventory"[tiab] OR BDI[tiab] OR BDI-II[tiab] OR
"beck anxiety inventory"[tiab] OR BAI[tiab] OR "Hamilton Rating
Scale"[tiab] OR Hamilton[tiab] OR "Hamilton rating scale for de-
pression"[tiab] OR HDRS[tiab] OR "Hamilton depression rating sca-
le"[tiab] OR HAMD[tiab] OR "HDRS-D"[tiab] OR "Hamilton rating scale
for anxiety"[tiab] OR "HDRS-A"[tiab] OR "Pittsburgh sleep quality in-
dex"[tiab] OR PSQI[tiab] OR inﬂammation[MeSH] OR inﬂammation
[tiab] OR "inﬂammatory markers"[tiab] OR "C-reactive protein"[MeSH]
OR "C-reactive protein"[tiab] OR CRP[tiab])
2.2. Inclusion and exclusion criteria
RCTs complying with the following criteria were included in meta-
analysis: human trials with either cross-over design or parallel, trials
with data on the eﬀects of saﬀron on parameters of mental health and
CRP with standard deviation (SD) and related 95 % conﬁdence interval
(CI) for the both intervention and placebo groups). Other studies such
as animal experiments, in vitro studies, case reports, observational
studies, trials without a control group, and studies that did not achieve
the least quality score were excluded from this meta-analysis.
2.3. Data extraction and quality assessment
Two independent authors (AG and EA) screened the articles based
on the eligibility criteria. As the ﬁrst step the titles and abstracts of
studies were reviewed. Then, the full-text of relevant studies was as-
sessed to ascertain the suitability of a study for the meta-analysis. Any
disagreement was resolved by the judgment of the third author (ZA).
Following data were taken from selected studies: the ﬁrst authors’
name, study location, year of publication, sample size, age, study de-
sign, dosage of saﬀron, duration of study, type of the disease, the mean
and SD for BDI, BAI, HAMD and CRP in the intervention and control
groups. The quality of the selected RCTs was independently assessed by
the same authors using the Cochrane Collaboration risk of bias tool17
based on the following criteria: "randomization generation, allocation
concealment, blinding of participants and outcome assessors, in-
complete outcome data, and selective outcome reporting, and other
sources of bias".
2.4. Data synthesis and statistical analysis
The eﬀects of saﬀron consumption on the changes of the following
parameters were calculated: 1) BDI, 2) BAI, 3) HAMD and 4) CRP.
Weighted mean diﬀerence (WMD) with 95 % CI was used for pooling
data to determine the eﬀect sizes. The change score approach was used
to calculate the eﬀect size of saﬀron intake on the analyzed parameter.
The random-eﬀect model was used to report the pooled eﬀect sizes
using 95 % CI.18 To calculate the SD changes, the following formula
was used: SD = square root [(SD pre-treatment)2 (SD posttreatment)2 -
(2R × SD pre-treatment × SD post-treatment)], correlation coeﬃcient
(R-value) was considered 0.9.19 When an SEM or SE was reported in-
stead of SD, the SD was calculated based on the following formula: SD
= SEM × √n (n = sample size in each group).
2.5. Heterogeneity and publication bias
Heterogeneity of included studies was assessed using Cochrane’s Q
test (with signiﬁcant P-value< 0.1) and I-square test (I2 greater than 50
percent showing signiﬁcant heterogeneity). The funnel plot, as well as
the Beggs’s and Egger’s regression tests were used to determine the
publication bias. STATA 11.0 (Stata Corp., College Station, TX) was
applied for data analysis.
3. Results
3.1. Characteristics of studies
Twenty one trials which were published between 2005 and 2019
were included in this systematic review and meta-analysis. Flow-dia-
gram for study selection is shown in Fig. 1. 1052 subjects, 563 in in-
tervention and 489 in control groups, were enrolled in included studies.
Characteristics of included studies are summarized in Table 1. The
dosages of saﬀron varied between 22 to 1000 mg/day, with a duration
range between 4 and 12 weeks. Results of quality assessment showed
that the quality of all included studies was high.
3.2. The eﬀects of saﬀron on parameters of mental health
Consumption of saﬀron resulted in a signiﬁcant reduction in BDI (11
studies with 12 eﬀect size) (WMD: -4.86; 95 % CI: -6.58, -3.14) (Table 2
& Fig. 2A), BAI (5 studies) (WMD: -5.29; 95 % CI: -8.27, -2.31) (Table 2
& Fig. 2C) and PSQI scores (3 studies with 4 eﬀect size) (WMD: -2.22;
95 % CI: -2.73, -1.72) (Table 2 & Fig. 2D). Saﬀron intake did not aﬀect
HDRS-D (6 studies) (WMD: -1.61; 95 % CI: -5.81, 2.58) (Table 2 &
Fig. 2B) and HARS-A scores (WMD: -2.74; 95 % CI: -5.76, 0.27) (Table 2
& Fig. 2E). The ﬁndings of the eﬀects of saﬀron on BDI and BAI did not
change in subgroup analysis (Table 3). However, HDRS-D score became
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signiﬁcant in studies using saﬀron in non-depressed (WMD: 3.76; 95 %
CI: 2.93, 4.58), in studies in which the duration of intervention was≥8
(WMD: 3.32; 95 % CI: 2.52, 4.11), in subjects with age<50 years
(WMD: 3.86; 95 % CI: 2.94, 4.79) and> 50 years (WMD: 0.94; 95 % CI:
0.01, 1.86) (Table 3).
3.3. The eﬀects of saﬀron on CRP levels
Saﬀron intake did not aﬀect CRP levels (WMD: -0.71; 95 % CI:
-1.66, 0.23) (Table 2 & Fig.2F).
3.4. Publication bias
Publication bias was evaluated by Egger’s test. The results indicated
no evidence of publication bias in the meta-analysis for the eﬀects of
saﬀron intake on HARS-A (P = 0.660), BAI (P = 0.857) and CRP (P =
0.825). However, there was publication bias for HDRS-D (P = 0.013),
BDI (P<0.001) and PSQI (P = 0.015).
4. Discussion
Depression and anxiety are serious mental disorders.20,21 Various
drugs have been used to treat these mental disturbances, but they are
associated with signiﬁcant adverse eﬀects. Some studies have in-
vestigated the beneﬁcial eﬀects of herbal medicines, including saﬀron
in the treatment of depression and anxiety.22–24 The purpose of our
study was to present a meta-analysis of RCTs examining the eﬀective-
ness of Crocus sativus L., commonly known as saﬀron, on parameters of
mental health and CRP. This meta-analysis demonstrated that saﬀron
intake signiﬁcantly reduced BDI, BAI and PSQI scores, but did not aﬀect
HDRS-D, HARS-A scores and CRP levels. Few meta-analyses have pre-
viously evaluated the eﬀects of consuming saﬀron on symptoms of
depression and anxiety. However, the results of one of these meta-
analysis are questionable because of evidence of publication bias and
lack of regional diversity and the other meta-analysis was more directed
towards the eﬀects of saﬀron on the severity of depression and
comparison with tested antidepressant drugs.25,26 The results of an-
other meta-analysis indicated that the eﬀects of saﬀron on MDD did not
diﬀer from the eﬀects of synthetic antidepressants.27 However, previous
meta-analyses have assessed the eﬀects saﬀron intake on symptoms of
depression and anxiety,25 and only depression,27,28 we have evaluated
the eﬀects of saﬀron on mental health parameters such as BDI, BAI,
PSQI, HDRS-D and HARS-A scores, and CRP levels.
4.1. Eﬀects on parameters of mental health
This meta-analysis showed that saﬀron intake signiﬁcantly reduced
BDI, BAI and PSQI scores, but did not aﬀect HDRS-D and HARS-A
scores. Several interesting data have been reported about the anti-
depressant and anti-anxiety properties of saﬀron based upon preclinical
and clinical studies. A number of RCTs demonstrated that saﬀron and
its active constituents have antidepressant properties similar to those of
antidepressant drugs such as ﬂuoxetine, imipramine and citalopram,
but with less adverse eﬀects. An older meta-analysis by Hausenblas
et al. 28, indicated that saﬀron might improve symptoms of depression
in adults with MDD but this meta-analysis has included only trials from
one country. Data from two reviews have suggested that saﬀron can
improve the symptoms and eﬀects of depression, premenstrual syn-
drome, sexual dysfunction and infertility, and excessive snacking be-
haviors.28,29 In the study by Mazidi et al.,30 taking 50 mg/twice daily
saﬀron for 12 weeks by patients with anxiety and depression resulted in
a signiﬁcant reduction in BDI and BAI scores. In another study, crocin
administration for 4 weeks in patients with MDD had favorable eﬀects
on mental health parameters, including depression, anxiety, general
health, and mood disorders.31 Saﬀron intake at a dosage of 15 mg/twice
daily for 8 weeks by mothers with mild-to-moderate postpartum de-
pressive disorder signiﬁcantly reduced their BDI-II scores.32 However,
in a pilot trial comparing the eﬃcacy of Crocus sativus L. with ﬂuoxetine
in depressed adult outpatients by Akhondzadeh Basti et al.33, petal of C.
sativus consumption at a dosage of 15 mg/day for 8 weeks was found to
be eﬀective similar to ﬂuoxetine in the treatment of mild to moderate
depression and there were no signiﬁcant diﬀerences in the two groups
concerning adverse eﬀects.. In another study, comparing the eﬃcacy of
30 mg/day saﬀron with 40 mg/day ﬂuoxetine for 6 weeks, saﬀron
capsules intake showed the same antidepressant eﬃcacy when com-
pared with ﬂuoxetine in patients with mild to moderate depression who
had undergone percutaneous coronary intervention.13 The eﬀects of
saﬀron on parameters of mental health might be a result of a synergistic
function of several constituents, including crocin, safranal, picrocrocin,
and ﬂavonoids.34 The exact mechanism of action of saﬀron in the brain
and its eﬀects on mental health scores is still not clear. Saﬀron might
inhibit reuptake of monoamine neurotransmitters, including nor-
epinephrine, dopamine, and serotonin in synapses.35 The eﬀects saﬀron
on mental health parameters may be also due to its antioxidant eﬀects
and inhibiting pro-inﬂammatory proﬁles and free radicals.36
4.2. Eﬀects on CRP levels
We found that saﬀron administration did not aﬀect CRP levels.
Results of saﬀron administration on inﬂammatory markers are con-
troversial. In a study by Hosseini et al.37, saﬀron administration at a
dosage of 100 mg/day for 8 weeks in subjects with allergic asthma
decreased signiﬁcantly hs-CRP levels. We have previously shown that
taking crocin for 8 weeks by subjects under methadone maintenance
treatment, was associated with a signiﬁcant reduction in hs-CRP le-
vels.38 However, taking saﬀron (1 g/day) for 8 weeks in patients with
type 2 diabetes mellitus (T2DM) did not have any eﬀects on CRP le-
vels.39 Diﬀerent study designs, lack of considering baseline values of
dependent variables and diﬀerent characteristics of study patients,
diﬀerent dosages of saﬀron as well as diﬀerent duration of studies
might be some of the reasons for these discrepant ﬁndings. Anyhow,
intake of saﬀron and crocin may decrease inﬂammatory markers
Fig. 1. Literature search and review ﬂowchart for selection of studies.
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Table 2
The eﬀects of saﬀron intake on parameters of mental health and C-reactive protein.
Variables Number of eﬀect sizes Weighted mean diﬀerence CI 95 % P- value Heterogeneity
I2 (%) P- value heterogeneity
BDI 12 −4.86 −6.58, -3.14 < 0.001 93.0 % <0.001
HDRS-D 6 −1.61 −5.81, 2.58 0.452 97.1 % <0.001
BAI 5 −5.29 −8.27, -2.31 < 0.001 93.9 % <0.001
PSQI 4 −2.22 −2.73, -1.72 < 0.001 3.6 % 0.375
HARS-A 3 −2.74 −5.76, 0.27 0.074 90.9 % <0.001
CRP 3 −0.71 −1.66, 0.23 0.139 89.4 % <0.001
BDI, Beck Depression Inventory; HDRS-D, Hamilton Depression Rating Scale; BAI, Beck Anxiety Inventory; PSQI, Pittsburgh Sleep Quality Index; HARS-A, Hamilton
Anxiety Rating Scale; CRP, C-reactive protein.
Fig. 2. A–F.Meta-analysis parameters of mental health and CRP weighted mean diﬀerence estimates for A) BDI, B) HDRS-D, C) BAI, D) PSQI, E) HARS-A, and F) CRP
levels in the saﬀron and placebo groups (CI = 95 %).
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through downregulation of mitogen-activated protein kinase (MAPK)
and MAPKAP signaling pathway and miRNA-122 expression40 and in-
hibiting apoptosis.41
This meta-analysis has several limitations. Various doses of saﬀron
and diﬀerent types of saﬀron as powder, extracts and pure crocin were
administered in the included studies that may have diﬀerent eﬀects on
mental health parameters. Due to the heterogeneity between studies, as
a result of variations in the dosage, frequency, or duration of saﬀron
intake, the results of this meta-analysis should be interpreted with
caution. We were unable to evaluate the dose response association
between supplementation dose and mental health parameters due to
the relatively small number of studies included. Also, we did not
evaluate the residual confounding and bias of each study that could not
be addressed through pooling. Heterogeneity for CRP and HARS-A was
high. This may be due to a low quality of methodology within the pa-
pers. Therefore, this should be considered in the interpretation of our
ﬁndings.
However, there are also several strengths of this study. More studies
which were included in this meta-analysis and longer period of sup-
plementation in included trials have provided added value to this meta-
analysis. In addition, we relied on independent judgment in which
diﬀerent reviewers independently performed the systematic review
process.
5. Conclusions
This meta-analysis demonstrated that saﬀron intake signiﬁcantly
reduced BDI, BAI and PSQI scores, but did not aﬀect HDRS-D, HARS-A
scores and CRP levels.
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